• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改良的Albumin-Bilirubin 分级优化用于 II-III 期胃癌患者的风险分层。

Modified Albumin-Bilirubin Grade optimized for risk stratification of patients with stage II-III gastric cancer.

机构信息

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.

Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan.

出版信息

Surg Today. 2023 Oct;53(10):1149-1159. doi: 10.1007/s00595-023-02669-x. Epub 2023 Mar 24.

DOI:10.1007/s00595-023-02669-x
PMID:36961609
Abstract

PURPOSE

The albumin-bilirubin (ALBI) grade is calculated using albumin and bilirubin values. We determined the optimal cutoff value of the ALBI grade for predicting the postoperative prognosis of gastric cancer (GC).

METHODS

We retrospectively reviewed a multicenter database of 3571 patients who underwent gastrectomy for GC between January 2010 and December 2014. The modified ALBI (mALBI) grade was determined using cutoff values: grade 1 (mALBI ≤  - 2.70), 2 (mALBI - 2.70 to - 2.10), and 3 (mALBI >  - 2.10). We used a validation cohort to evaluate reproducibility.

RESULTS

The entire cohort (n = 956) was randomly assigned to the learning or validation cohorts (n = 478 each). The former was categorized into the following groups by the preoperative mALBI grade: grade 1 (n = 235), grade 2 (n = 162), and grade 3 (n = 81). The disease-specific survival (DSS) rates of the learning and validation cohorts were significantly shortened in association with higher mALBI grade (learning, p = 0.0068; validation, p = 0.0100). A multivariate analysis revealed that mALBI grade 3 served as an independent prognostic factor for DSS. Furthermore, mALBI grade 2 or 3 was associated with a greater risk of disease-specific death in most subgroups.

CONCLUSION

The mALBI grade accurately predicted the long-term postoperative prognosis of locally advanced GC.

摘要

目的

ALBI 分级是通过白蛋白和胆红素值计算得出的。我们确定了 ALBI 分级预测胃癌(GC)术后预后的最佳截断值。

方法

我们回顾性分析了 2010 年 1 月至 2014 年 12 月期间接受 GC 胃切除术的 3571 例患者的多中心数据库。使用以下截断值确定改良 ALBI(mALBI)分级:1 级(mALBI ≤-2.70)、2 级(mALBI-2.70 至-2.10)和 3 级(mALBI>-2.10)。我们使用验证队列来评估可重复性。

结果

整个队列(n=956)被随机分配到学习或验证队列(n=478 例)。前者根据术前 mALBI 分级分为以下几组:1 级(n=235)、2 级(n=162)和 3 级(n=81)。学习和验证队列的疾病特异性生存率(DSS)与 mALBI 分级升高显著缩短(学习队列,p=0.0068;验证队列,p=0.0100)。多变量分析显示,mALBI 分级 3 是 DSS 的独立预后因素。此外,mALBI 分级 2 或 3 与大多数亚组中疾病特异性死亡的风险增加相关。

结论

mALBI 分级准确预测了局部晚期 GC 的长期术后预后。

相似文献

1
Modified Albumin-Bilirubin Grade optimized for risk stratification of patients with stage II-III gastric cancer.改良的Albumin-Bilirubin 分级优化用于 II-III 期胃癌患者的风险分层。
Surg Today. 2023 Oct;53(10):1149-1159. doi: 10.1007/s00595-023-02669-x. Epub 2023 Mar 24.
2
Prognostic Value of a Modified Albumin-Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection.改良白蛋白-胆红素评分对根治性切除术后食管鳞癌患者的预后价值。
Ann Surg Oncol. 2022 Aug;29(8):4889-4896. doi: 10.1245/s10434-022-11654-6. Epub 2022 Apr 5.
3
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.白蛋白-胆红素评分在预测接受雷莫芦单抗治疗的日本晚期肝细胞癌患者结局中的作用:一项真实世界研究。
Oncology. 2021;99(4):203-214. doi: 10.1159/000511734. Epub 2020 Dec 4.
4
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.白蛋白-胆红素分级在日本46681例肝细胞癌患者全国性调查中的验证、潜力及预后评估:对肝功能进行更详细评估的必要性
Liver Cancer. 2017 Nov;6(4):325-336. doi: 10.1159/000479984. Epub 2017 Sep 22.
5
A detailed assessment of liver function in patients with hepatocellular carcinoma via the modified albumin-bilirubin (mALBI) grade.通过改良白蛋白-胆红素(mALBI)分级对肝细胞癌患者的肝功能进行详细评估。
Am J Cancer Res. 2022 Jun 15;12(6):2711-2720. eCollection 2022.
6
Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices.改良ALBI分级与胃食管静脉曲张内镜检查结果的相关性
In Vivo. 2021 Mar-Apr;35(2):1163-1168. doi: 10.21873/invivo.12364.
7
Modified Albumin-Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy.用于对接受抗癌治疗的肝细胞癌患者生存情况进行分层的改良白蛋白-胆红素模型
Cancers (Basel). 2022 Oct 17;14(20):5083. doi: 10.3390/cancers14205083.
8
Preoperative Albumin-Bilirubin Grade Predicts Recurrences After Radical Gastrectomy in Patients with pT2-4 Gastric Cancer.术前白蛋白-胆红素分级可预测pT2-4期胃癌患者根治性胃切除术后的复发情况。
World J Surg. 2018 Mar;42(3):773-781. doi: 10.1007/s00268-017-4234-x.
9
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.改良ALBI分级在肝细胞癌患者肝功能更详细评估中的验证:一项多中心分析
Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.
10
Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).基于改良的白蛋白-胆红素评分(ALBS 分级)提出的血清白蛋白作为仑伐替尼治疗肝细胞癌患者的预后因素的时序变化:白蛋白简化分级建议。
J Gastroenterol. 2022 Aug;57(8):581-586. doi: 10.1007/s00535-022-01883-7. Epub 2022 Jun 28.

引用本文的文献

1
Preoperative albumin-bilirubin grade combined with sarcopenia predicts long-term outcomes after laparoscopic gastrectomy for advanced gastric cancer.术前白蛋白-胆红素分级联合肌肉减少症可预测进展期胃癌腹腔镜胃切除术后的长期预后。
BMC Gastroenterol. 2025 Aug 1;25(1):550. doi: 10.1186/s12876-025-04173-7.

本文引用的文献

1
Prognostic Value of a Modified Albumin-Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection.改良白蛋白-胆红素评分对根治性切除术后食管鳞癌患者的预后价值。
Ann Surg Oncol. 2022 Aug;29(8):4889-4896. doi: 10.1245/s10434-022-11654-6. Epub 2022 Apr 5.
2
Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib.白蛋白-胆红素评分与接受瑞戈非尼二线化疗的结直肠癌患者的相关性。
Int J Clin Oncol. 2021 Jul;26(7):1257-1263. doi: 10.1007/s10147-021-01910-2. Epub 2021 Apr 11.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Efficacy of the Preoperative Albumin-Bilirubin Grade for Predicting Survival and Outcomes of Postoperative Chemotherapy for Advanced Gastric Cancer.术前白蛋白-胆红素分级对预测晚期胃癌生存及术后化疗结局的效能
Cancer Manag Res. 2020 Nov 20;12:11921-11932. doi: 10.2147/CMAR.S279782. eCollection 2020.
5
Amido-Bridged Nucleic Acid-Modified Antisense Oligonucleotides Targeting to Treat Peritoneal Metastasis of Gastric Cancer.靶向治疗胃癌腹膜转移的酰胺桥连核酸修饰反义寡核苷酸
Mol Ther Nucleic Acids. 2020 Oct 6;22:791-802. doi: 10.1016/j.omtn.2020.10.001. eCollection 2020 Dec 4.
6
Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer.针对神经元五聚素受体的治疗性单克隆抗体控制胃癌转移。
Mol Cancer. 2020 Aug 26;19(1):131. doi: 10.1186/s12943-020-01251-0.
7
A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.基于白蛋白-胆红素分级的米兰标准之外的肝细胞癌新预后模型。
Dig Dis Sci. 2020 Feb;65(2):658-667. doi: 10.1007/s10620-019-05813-1. Epub 2019 Oct 28.
8
Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus.改良全身炎症评分对食管鳞癌根治术后风险分层有用。
Ann Surg Oncol. 2019 Dec;26(13):4773-4781. doi: 10.1245/s10434-019-07914-7. Epub 2019 Oct 11.
9
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.改良ALBI分级在肝细胞癌患者肝功能更详细评估中的验证:一项多中心分析
Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.
10
Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.四项疗程与八项疗程辅助 S-1 治疗 II 期胃癌患者(JCOG1104 [OPAS-1]):一项开放标签、III 期、非劣效性、随机试验。
Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22.